Welcome to the LDN Radio Show brought to you by the LDN Research Trust. I'm your host Linda Elsegood. Today we're joined by Ray Solano from PD Labs. He's also a nutritionist. Could you tell us a bit of background about yourself?

Welcome to the LDN Radio Show brought to you by the LDN Research Trust. I'm your host Linda Elsegood. 

Dr Steve Zielinski is here today. Can you tell us who are you? What made you decide you wanted to be a pharmacist? 

28 June 2023

Welcome to the LDN Radio show brought to you by the LDN Research Trust.   I'm your host Linda Elsegood. Today we're joined by Kim from the United States who uses LDN for Hashimoto's and Sjögren's syndrome.

Thank you for joining us today, Kim.  Can you tell us what your life was like before you got sick?

The Toronto Functional Medicine Centre IV Lounge Explains How Nutritional Support May Help Manage Fibromyalgia and Chronic Fatigue Syndrome

Emedicodiary Publishes Article Discussing the Ways LDN Possibly Helps with Rare Diseases

Digital Journal
01 May 2023
https://www.digitaljournal.com/pr/news/get-featured/emedicodiary-publishes-article-discussing-the-ways-ldn-possibly-helps-with-rare-diseases

Will LDN therapy improve the quality of life of patients with fibromyalgia? (in Polish) (News)

05 May 2023
Medexpress.pl
https://www.medexpress.pl/blogosfera/czy-terapia-ldn-poprawi-jakosc-zycia-pacjentow-z-fibromialgia/

Pain associated with fibromyalgia: Benefits from low-dose naltrexone (in Italian)

National Courier
22 May 2023
https://www.corrierenazionale.it/2023/05/22/dolore-associato-alla-fibromialgia-benefici-da-basse-dosi-di-naltrexone/?noamp=mobile

Low-Dose Naltrexone Could Treat Long COVID Symptoms

verywellhealth
07 June 2023
https://www.verywellhealth.com/low-dose-naltrexone-long-covid-treatment-7507283

A systematic literature review on the clinical efficacy of low dose naltrexone and its effect on putative pathophysiological mechanisms among patients diagnosed with fibromyalgia

Heliyon
19 April 2023
https://pubmed.ncbi.nlm.nih.gov/37206027/

Low-Dose Naltrexone in Rheumatological Diseases

Mediterr J Rheumatol
31 March 2023
https://pubmed.ncbi.nlm.nih.gov/37223594/

Background: Naltrexone has been approved for alcohol and opioid abuse by the FDA. At low-dose naltrexone (LDN) has been used in several diseases including chronic pain and autoimmune conditions, including rheumatic disorders.